文献速递新生儿儿童内分泌与遗传代谢

危重婴儿基因组检测整合的变异发现与挑战:GEMINI研究中报告

Novel Variant Findings and Challenges Associated With the Clinical Integration of Genomic Testing: An Interim Report of the Genomic Medicine for Ill Neonates and Infants (GEMINI) Study.
PubMed 文献 · JAMA Pediatr · 2021-05-03

GEMINI研究是一项前瞻性多中心临床试验,比较快速全基因组测序与针对婴儿期疾病设计的1722个可操作基因的靶向基因组平台。51例阳性病例中34例(67%)因靶向平台技术局限、变异解读、过滤差异或多重原因导致结果报告不同。

要点

  • 两平台结果一致率73%,致病/可能致病变异检出率33%。
  • 检出致病/可能致病变异者中78%出现显著临床管理改变。
  • 阳性病例中67%因技术或解读差异导致报告结果不同。

核心结论

  • 现有基因组测序技术具有关键的变异检测能力,但其显著局限性必须被更好地理解。

研究设计与样本

  • GEMINI研究为前瞻性多中心临床试验,计划入组400例,在美国6家医院开展。
  • 纳入住院的1岁以下疑似遗传病婴儿,本次报告前113例入组患者结果。
  • 患者及父母(可得时组成 trio)同时接受两种基因组平台检测,各实验室独立进行表型驱动解读且互盲。

主要发现

  • 113例患儿胎龄23至40周,月经后年龄27至83周,男性67例(59%)。
  • 51例(45%)返回诊断和/或意义不明变异(VUS),62例(55%)结果为阴性。
  • 14例(12%)检出可能与表型相关的VUS,诊断中位日龄为22天(范围3-313天)。
  • 29例(78%)携带P/LP变异的婴儿出现显著临床管理改变,7个 trio 报告了偶然发现。

关键数值与推荐

  • 变异按美国医学遗传学与基因组学学会(ACMG)标准分类为致病(P)、可能致病(LP)或意义不明变异(VUS)。
  • 靶向基因组平台包含1722个可操作基因,针对婴儿期出现的疾病。
  • 51例阳性病例中34例(67%)因靶向平台技术局限、变异解读、过滤差异或多重原因导致报告结果不同。

临床怎么用

  • 对疑似遗传病的住院婴儿,临床可考虑同时或序贯使用快速全基因组测序与靶向基因组平台以提高变异检出。
  • 解读阳性结果时需注意靶向平台可能因技术局限或过滤差异漏检或报告不同变异。
  • 检出P/LP变异后应评估对临床管理的潜在影响,本研究中78%出现显著管理改变。

局限性

  • 本报告为中期分析,仅纳入前113例患者,最终计划入组400例。
  • 研究仅在美国6家医院开展,结果外推需谨慎。
  • 原文未报告靶向平台与快速全基因组测序的灵敏度、特异性等诊断性能指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A targeted genomic sequencing platform focused on diseases presenting in the first year of life may minimize financial and ethical challenges associated with rapid whole-genomic sequencing. OBJECTIVE: To report interim variants and associated interpretations of an ongoing study comparing rapid whole-genomic sequencing with a novel targeted genomic platform composed of 1722 actionable genes targeting disorders presenting in infancy. DESIGN, SETTING, AND PARTICIPANTS: The Genomic Medicine in Ill Neonates and Infants (GEMINI) study is a prospective, multicenter clinical trial with projected enrollment of 400 patients. The study is being conducted at 6 US hospitals. Hospitalized infants younger than 1 year of age suspected of having a genetic disorder are eligible. Results of the first 113 patients enrolled are reported here. Patient recruitment began in July 2019, and the interim analysis of enrolled patients occurred from March to June 2020. INTERVENTIONS: Patient (proband) and parents (trios, when available) were tested simultaneously on both genomic platforms. Each laboratory performed its own phenotypically driven interpretation and was blinded to other results. MAIN OUTCOMES AND MEASURES: Variants were classified according to the American College of Medical Genetics and Genomics standards of pathogenic (P), likely pathogenic (LP), or variants of unknown significance (VUS). Chromosomal and structural variations were reported by rapid whole-genomic sequencing. RESULTS: Gestational age of 113 patients ranged from 23 to 40 weeks and postmenstrual age from 27 to 83 weeks. Sixty-seven patients (59%) were male. Diagnostic and/or VUS were returned for 51 patients (45%), while 62 (55%) had negative results. Results were concordant between platforms in 83 patients (73%). Thirty-seven patients (33%) were found to have a P/LP variant by 2 or both platforms and 14 (12%) had a VUS possibly related to phenotype. The median day of life at diagnosis was 22 days (range, 3-313 days). Significant alterations in clinical care occurred in 29 infants (78%) with a P/LP variant. Incidental findings were reported in 7 trios. Of 51 positive cases, 34 (67%) differed in the reported result because of technical limitations of the targeted platform, interpretation of the variant, filtering discrepancies, or multiple causes. CONCLUSIONS AND RELEVANCE: As comprehensive genetic testing becomes more routine, these data highlight the critically important variant detection capabilities of existing genomic sequencing technologies and the significant limitations that must be better understood.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Maron JL, Kingsmore SF, Wigby K, et al. Novel Variant Findings and Challenges Associated With the Clinical Integration of Genomic Testing: An Interim Report of the Genomic Medicine for Ill Neonates and Infants (GEMINI) Study. JAMA Pediatr. 2021. PMID: 33587123. doi:10.1001/jamapediatrics.2020.5906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。